studied the delivery IFN-β in a targeted manner using IFN-β-antibody constructs, and reported that this method boosted the cross-presentation of tumor antigens by CD8α DCs, resulted in the activation of CD8+ T lymphocytes, and mediated tumor outgrowth suppression (178). This evidence concerns the gene CD8A and neoplasm.